Azoulay Salomon
Known title: Chief Medical OfficerCIK: 0002030246
Associated companies
Transaction History
| MBX | ▼ Sell | Open Market | 370 | $24K | 8/4/2026 | View on chart |
| MBX | ▲ Buy | Option Exercise | 55,000 | $575K | 5/8/2026 | View on chart |
| MBX | ▼ Sell | Open Market | 55,000 | $2.1M | 5/8/2026 | View on chart |
| MBX | ▲ Buy | Option Exercise | 15,003 | $240K | 5/8/2026 | View on chart |
| MBX | ▼ Sell | Open Market | 15,003 | $575K | 5/8/2026 | View on chart |
| MBX | ▼ Sell | Open Market | 231 | $7K | 5/6/2026 | View on chart |
| MBX | ▲ Buy | Grant | 15,000 | $0 | 2/2/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised
MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised. MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.